Related Experiment Video
Updated: Mar 19, 2026

Transesophageal Atrial Burst Pacing for Atrial Fibrillation Induction in Rats
Published on: February 14, 2022
Vericiguat Alleviates Atrial Electrical and Structural Remodeling in Rats with Atrial Fibrillation
Xia Zhang1, Yubing Wang1, Liangchen Shen1
1Department of Cardiovascular Medicine, Affiliated Hospital of North Sichuan Medical College, Nanchong, China.
Background:
The initiation and maintenance of atrial fibrillation (AF) are predominantly driven by progressive atrial structural remodeling, characterized by fibrosis and electrical conduction abnormalities. While vericiguat has shown efficacy in attenuating cardiac remodeling in heart failure (HF), its impact on AF remains insufficiently characterized.
Methods:
This study investigated the cardioprotective effects of vericiguat in a Sprague-Dawley rat model of AF. Twenty-four male SD rats (250-300 g, 8-10 weeks old) were randomly assigned to control, AF, and vericiguat-treated groups. Echocardiography and histological assessments were performed, along with quantification of NT-proBNP, Collagen I, CaMKII, Cx43, ATG7, P62, and LC3II/I in the left atrium.
Results:
Compared to controls, AF rats exhibited atrial enlargement, elevated myocardial fibrosis, and significant alterations in molecular markers. Vericiguat treatment effectively reversed these pathological changes. Specifically, NT-proBNP, Collagen I, CaMKII, ATG7, and LC3II/I were upregulated, while Cx43 and P62 were downregulated in the AF group-changes that were mitigated by vericiguat.
Conclusion:
Collectively, these findings suggest that vericiguat attenuates atrial remodeling and AF progression by modulating autophagy and suppressing fibrosis.
More Related Videos
Related Concept Videos
ECG Interpretation of Arrhythmias II: Atrial, Junctional and Ventricular Arrhythmias
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers
Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers
Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...

